Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Monday, 18 December 2017, 13:40 HKT/SGT
Share:
    

Source: Eisai
Eisai Launches Educational Materials for Understanding Dementia
And Thinking About What One Can Do for Elementary and Secondary School Students in Japan

TOKYO, Dec 18, 2017 - (JCN Newswire) - Eisai Co., Ltd. announced that it has created educational materials for understanding dementia and thinking about what one can do for elementary and secondary school students, and has commenced marketing these materials primarily to local governments, educational institutions as well as medical and nursing care professionals from today.

Five types of materials have been created, an educational DVD, textbooks for elementary and secondary school students as well as guides for instructors for each textbook. The DVD is a live action drama that tells the story of a family whose grandmother has dementia, and the contents enable viewers to learn what is dementia, the feelings of someone with dementia, and how to interact with people with dementia. In addition to an outline of the DVD, the textbooks contain basic knowledge on the aging society and dementia, as well as points on how to interact with people with dementia. The textbooks can be used in lessons or group work. The contents of the guides for instructors include model lesson plans, question and answer ideas and reference materials, as well as worksheets that can be used in group work.

Yukimichi Imai MD., PhD., president of the Japanese Society for Dementia Care, Director of Wako Hospital and supervisor for these materials, stated: "he person that begins suffering dementia is the one who is most distressed, and changes in symptoms may occur depending on how their family and friends act. In addition, the number of people with dementia in 2025 is estimated to reach approximately 7 million, affecting one out of every five elderly people aged over 65. However, with the rise of the nuclear family, there are more and more children and students who have few opportunities to interact with people with dementia. We believe that learning about dementia at school and thinking together about the feelings of those with dementia and how to interact with them will be a very important first step in this era of a progressively aging society. I highly endorse Eisai' efforts in creating these educational materials to think about living together with dementia."

Hideki Hayashi, representative corporate officer, Japan Business and CIO, Eisai, commented: "During our work on building communities that co-exist with dementia in collaboration with local governments, medical and nursing care professionals as well as other stakeholders, we recognized the need for dementia education in the classroom, and created educational materials that can be used in lessons such as group work to think about the feelings of people with dementia and how to interact with them, as well as for gaining knowledge on dementia. Through these materials, we hope that children will become concerned about their own grandparents and the state of elderly people in public spaces as a member of the local community, and that this will spark responses such as consulting surrounding adults when they sense something is amiss."


About Eisai

Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our human health care philosophy by delivering innovative products in various therapeutic areas with high unmet medical needs, including Oncology and Neurology.

As a global pharmaceutical company, our mission extends to patients around the world through our investment and participation in partnership-based initiatives to improve access to medicines in developing and emerging countries.

For more information about Eisai Co., Ltd., please visit www.eisai.com.

Contact:
Public Relations Department,
Eisai Co., Ltd.
+81-3-3817-5120


Dec 18, 2017 13:40 HKT/SGT
Source: Eisai

Eisai (TSE: 4523)

Topic: Press release summary
Sectors: BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2018 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
Sept 5, 2018 14:28 HKT/SGT
Eisai And Merck & Co. Announce China NMPA Approval of First Approval for LENVIMA (Lenvatinib) for Treatment of Unresectable HCC
Sept 3, 2018 14:50 HKT/SGT
Eisai Receives Approval for Partial Label Change for Vascular Embolization Device DC Bead
Aug 30, 2018 09:36 HKT/SGT
Eisai's LENVIMA (LENVATINIB) Capsules Approved for First-Line Treatment of Unresectable Hepatocellular Carcinoma (HCC) in South Korea
Aug 29, 2018 10:25 HKT/SGT
Biogen and Eisai Report Data from Long-Term Extension Phase 1b Study of Investigational Alzheimer's Disease Treatment Aducanumab
Aug 28, 2018 09:11 HKT/SGT
Eisai: Long-Term Cardiovascular Outcomes Data for Anti-Obesity Agent BELVIQ
Aug 23, 2018 08:00 HKT/SGT
Eisai: European Commission Grants Marketing Authorization for LENVIMA (Lenvatinib)
July 31, 2018 14:13 HKT/SGT
Eisai Signs Collaboration Agreement for Anti-Obesity Agent Lorcaserin in China to CY Biotech
July 31, 2018 10:27 HKT/SGT
Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. Announce U.S. FDA Grants Breakthrough Therapy Designation for LENVIMA
July 26, 2018 10:34 HKT/SGT
Eisai and Biogen Announce Detailed Results of Phase II Clinical Study of BAN2401 in Early Alzheimer's Disease at AAIC 2018
July 26, 2018 08:01 HKT/SGT
Eisai and Biogen Present Detailed Results from Phase II Clinical Study of Elenbecestat in MCI and Mild to Moderate Alzheimer's Disease at AAIC 2018
More news >>
 News Alerts
Copyright © 2018 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 10 8405 3688 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 6721 7212

Connect With us: